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303 The effect of sunshine on vitamin D levels (25-OHD) in cystic
ﬁbrosis (CF) patients − a UK experience
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1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
Introduction: Despite routine oral supplementation, levels of 25-OHD in CF patients
are often unsatisfactory. Although the aetiology is multi-factorial, reduced skin exposure
to sunlight is a contributory cause but there is no consensus as to when 25-OHD
levels should be estimated. We therefore compared the variation in 25-OHD levels and
monthly UK sunshine in our CF-patients, and also looked at any intra-patient variability
in relation to the month in which testing was performed.
Methods and Results: We compared 711 25-OHD estimations taken between 2004–
2010 from 240 adult CF patients (mean age 28 years, 173 [72%] receiving vitamin D
supplementation, 133 male) with average monthly sunshine data obtained from the
UK Meteorological Ofﬁce. A positive correlation was observed between the average
25-OHD levels and average monthly UK sunshine (2004–2010) (Pearson’s coefﬁcient
r = 0.54, P< 0.03) (Table 1). 27 patients had >5 estimations of 25-OHD during the
study period: same-patient variability expressed as the inter quartile difference (IQR),
dependent upon the month of testing (Table 2).
Table 1. Sunshine hours/25-OHD
Months Jan-Feb Mar-Apr May-Jun Jul-Aug Sept-Oct Nov-Dec
Average sunshine
(h/mo)
54 119 177 170 108 49
25-OHD average level
(ng/ml)
16 15 19 31 21 16
Table 2. IQR difference (DIQR) of vitamin D level per month
Month Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
DIQR 2 14 6 8 15 13 18 20 15 6 8 18
Conclusions: Although higher 25-OHD levels were found in our patients with in-
creased sunshine during the UK summer months, overall levels of 25-OHD however
were low despite supplementation: the UK has less sunshine hours (average 1,476
hrs/year) than other major European countries (1,776 hrs/year). Monthly variation of
the IQR difference for the same patient suggests that measures should be taken to
ensure that 25-OHD levels are checked at the same time each year.
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Introduction: Cystic ﬁbrosis (CF) patients are at risk of developing vitamin K
deﬁciency. However, there is no reliable data in the youngest age group. Therefore,
we aimed to assess vitamin K status in children aged up to 3 years and to correlate
it with several clinical factors.
Material and Methods: The study comprised 52CF patients. In all subjects, the
concentration of the undercarboxylated prothrombin (PIVKA-II), as a marker of
vitamin K deﬁciency, was determined.
Results: PIVKA-II concentrations were pathological in 24 (46.2%) CF children,
in remaining 28 (53.8%) patients vitamin K status was found to be normal. No
statistical differences in clinical parameters (Z-score for body height and weight,
number of hospitalizations and sweat chloride concentrations) neither in distribution
of Pseudomonas aeruginosa colonization nor in pancreatic status between selected
subgroups with normal and abnormal PIVKA-II concentrations were documented.
Normal vitamin K status was more frequent in patients receiving proper vitamin
supplementation (p< 0.0078). However, vitamin K deﬁciency appeared in 5 out of
21 patients receiving at least 2.5mg vitamin K/week. In logistic regression model,
no clinical parameter was proven to be a risk factor for vitamin K deﬁciency.
Conclusion: Vitamin K deﬁciency is frequent in CF infants and toddlers, and may
also appear in those receiving recommended supplementation. There is no strong
relationship between clinical expression of the disease and vitamin K status.
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Objectives: Pancreatic insufﬁciency and fat and bile malabsorption predisposes
patients with cystic ﬁbrosis (CF) to fat-soluble vitamin malabsorption, despite
pancreatic enzyme replacement. Several studies have associated lung injury with
deﬁcit of antioxidants. The aim of our study was to analyze the relationship between
lung function and vitamin A in children and young adults with CF.
Methods: Multicenter descriptive and transversal study. During 2 consecutive
visits during the same year, we checked serum levels of vitamins A, D and
E in relation to functional pulmonary status obtained by espirometry in 94 CF
patients − 6 to 24 years old − in absence of clinical exacerbation (no cough, fever
or hemoptysis). Statistical analysis: Pearson and Spearman correlation coefﬁcients.
Multiple regression Analysis.
Results: The average dose of vitamin A supplementation was 3204±1223 units/
day. Serum vitamin A levels were positively correlated with FEV1 (r = 0.250
p = 0.015) and FEV25−75 (r = 0.250 p = 0.018). After adjusting for pancreatic status
(13% were pancreatic sufﬁcient), the same associations remained: FEV (B= 0.236
p = 0.018) and FEV25−75 (B = 0.324 p = 0.024). No correlations were found with
other vitamins (D and E).
Conclusion: Lung function in stable CF correlates and gradually improves as higher
the serum levels of vitamin A are. This relationship is independent of pancreatic
and vitamin D or E status.
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Objectives: Recent literature suggests that metabolism of fat-soluble vitamins
undergoes changes in organ transplantated patients. Cyclosporine A was found
to produce elevations in serum 1,25(OH)2D levels in animal models and kidney
transplanted patients. Vit D supplementation might decrease the need for immuno-
suppression. The role of vit D in the prevention of post-transplant osteoporosis
remains unclear.
Methods: Patient records of 41 lung transplanted CF patients at CF centres
in Lund and Stockholm were used to investigate the metabolism of fat-soluble
vitamins, importance of vit D for post-transplant bone health and its interactions
with immunosuppressant drugs. S-retinol and a-tocoferol levels increase after
lung transplantation (p< 0.001 and P< 0.005 respectively), whereas S-25OHD and
1,25(OH)2D levels do not change. Despite vit D supplementation, median S-25OHD
is insufﬁcient both before and after transplantation. Whole body, spinal and femoral
BMD correlate with P-calcium (p< 0.05 in all). Vit D supplementation is not
associated with higher P-calcium or BMD after transplantation. However, vit D sup-
plement dose correlates negatively with PTH (r = −0.88; p< 0.05). S-1,25(OH)2D
one year after transplantation is positively correlated with cumulative dose of
cyclosporine A (r = 0.93; p< 0.01). Cumulative dose of hydrocortisone needed
during the ﬁrst week after transplantation is inversely related to the cumulative
vit D supplement dose (r = −0.52;p< 0.05).
Conclusion: The observed changes in vit A and E metabolism, and the interference
of vitamin D with immunosuppressant drugs may have an impact on immune
modulation and bone health in lung transplanted CF patients.
